title: Double autologous stem cell transplantation for multiple myeloma: a Korean single center study.
abstract: BACKGROUND
  Although high dose chemotherapy coupled with an autologous stem cell transplantation (ASCT) is widely accepted as effective therapy for multiple myeloma (MM), few reports are available in Korea, especially in the area of double ASCT. We present the results of an institutional retrospective study of 12 patients with MM treated by double ASCT.
  
  
  METHODS
  Eligible patients received induction therapy using vincristine, adriamycin, dexamethasone (VAD), and mobilization was performed using cyclophosphamide plus lenograstim. High-dose melphalan (total 200 mg/m2) was used to condition the ASCT.
  
  
  RESULTS
  The median interval from diagnosis to ASCT was 6 months (range, 1.8-15.3 months). The median interval between the 1st and 2nd ASCT was 4.4 months (range 2.1-48.7 months). The median follow up was 18.3 months (range 8.1-50.5 months) for the nine surviving patients. No therapy-related mortality occurred. Following induction chemotherapy, two patients experienced CR. Following double ASCT, eight patients experienced CR. The 5 year OS was 59%. The median duration of event free survival was 2.13 years (95% CI, 0.84-3.42).
  
  
  CONCLUSIONS
  Although the results of study did not demonstrate the advantage of double ASCT, this is the first report to outline the outcome of double ASCT for Korean MM patients.
authors.affiliation: Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
authors.forename: Ock Bae
authors.initials: OB
authors.lastname: Ko
authors.forename: Shin
authors.initials: S
authors.lastname: Kim
authors.forename: Hyeok
authors.initials: H
authors.lastname: Shim
authors.forename: Jung-Hun
authors.initials: JH
authors.lastname: Lee
authors.forename: Jung-Min
authors.initials: JM
authors.lastname: Ahn
authors.forename: Soon-Man
authors.initials: SM
authors.lastname: Yoon
authors.forename: Min-Hyok
authors.initials: MH
authors.lastname: Jeon
authors.forename: Il-No
authors.initials: IN
authors.lastname: Do
authors.forename: So-young
authors.initials: SY
authors.lastname: Lee
authors.forename: Yong Gil
authors.initials: YG
authors.lastname: Kim
authors.forename: Sang We
authors.initials: SW
authors.lastname: Kim
authors.forename: Sung-Bae
authors.initials: SB
authors.lastname: Kim
authors.forename: Sang-Hee
authors.initials: SH
authors.lastname: Kim
authors.forename: Jung Shin
authors.initials: JS
authors.lastname: Lee
authors.forename: Wookun
authors.initials: W
authors.lastname: Kim
authors.forename: Chan-Jung
authors.initials: CJ
authors.lastname: Park
authors.forename: Hyun-sook
authors.initials: HS
authors.lastname: Chi
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007723:Korea; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D000078224:Lenograstim; D003907:Dexamethasone; D004317:Doxorubicin